(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/175033 A1

(51) International Patent Classification:
A61K 31/4184 (2006.01) *A61P 7/00* (2006.01)
A61P 37/04 (2006.01)

(21) International Application Number:
PCT/US2025/015829

(22) International Filing Date:
13 February 2025 (13.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/553,001 13 February 2024 (13.02.2024) US

(71) Applicant: **X4 PHARMACEUTICALS, INC.** [US/US]; 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (US).

(72) Inventors: **TAVERAS, Art**; c/o X4 Pharmaceuticals, Inc., 61 North Beacon Street, 4th Floor, BOSTON, Massachusetts 02134 (US). **STEINER, Deborah J.**; c/o X4 Pharmaceuticals, Inc., 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (US). **ARBET-ENGELS, Christophe Jean**; c/o X4 Pharmaceuticals, Inc., 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (US). **GARG, Varun**; c/o X4 Pharmaceuticals, Inc., 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (US).

(74) Agent: **SWICK, Steven** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: TREATMENT OF MEDICAL DISORDERS USING CXCR4 INHIBITORS

(57) Abstract: The present invention relates to methods of treating patients with neutropenia, such as severe chronic neutropenia, or a related disorder, in which a CXCR4 inhibitor such as mavorixafor, or a pharmaceutically acceptable salt thereof, is administered to such patients.

WO 2025/175033 A1